Aston Science

Aston Sci. Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Seoul, South Korea, focused on the development of innovative medicines in oncology, immunology, and geriatrics. The company specializes in therapeutic cancer vaccines and prophylactic vaccines using innovative delivery platforms including mRNA, DNA, and peptide-based modalities. Its proprietary Th-Vac platform employs AI-driven in silico epitope prediction technology to identify and design highly selective vaccine targets, enabling the development of personalized cancer vaccines. Aston Sci.'s lead asset AST-301 is a pDNA-based HER2-targeting therapeutic cancer vaccine currently in Phase 2 clinical trials (NCT05771584) for gastric cancer, which received FDA Orphan Drug Designation. The company leads the NeoVax-K Consortium, selected for Korea's ARPA-H initiative to develop personalized cancer vaccines. Aston Sci. also collaborates with BrezezBio on antigen-specific immune tolerance for autoimmune diseases and with Certest Pharma on mRNA cancer vaccine delivery systems, expanding its platform across therapeutic and prophylactic vaccine applications.